NAD+ 1G & TIRZEPATIDE'S SUCCESSOR : A UK UPDATE

The growing interest in NAD+ supplementation, particularly at a high dosage of one gram, continues to build within the UK healthcare community. At the same time , attention is firmly fixed on Retatrutide, a innovative GLP-1 receptor agonist being viewed by many as a potential replacement to Tirze